Scarica l'app Stockscreener
0.698
4.98%
0.0331
Precedente Chiudi:
$0.6649
Aprire:
$0.656
Volume 24 ore:
210.28K
Relative Volume:
0.36
Capitalizzazione di mercato:
$23.30M
Reddito:
-
Utile/perdita netta:
$-55.92M
Rapporto P/E:
-0.495
EPS:
-1.41
Flusso di cassa netto:
$-43.07M
1 W Prestazione:
+12.94%
1M Prestazione:
-8.29%
6M Prestazione:
-84.45%
1 anno Prestazione:
-51.19%
Intervallo 1D:
$0.6204
$0.70
Intervallo di 1 settimana:
$0.5655
$0.7223
Portata 52W:
$0.5655
$5.75
Skye Bioscience Inc Stock (SKYE) Company Profile
Nome
Skye Bioscience Inc
Settore
Industria
Telefono
(858) 410-0266
Indirizzo
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Compare SKYE vs MOBBW, GOODO, PSNYW, SHMD, DWLD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
MOBBW
Mobilicom Limited Warrants
|
1.90 | 2.52B | 0 | 0 | 0 | 0.00 |
GOODO
Gladstone Commercial Corporation
|
19.70 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.94 | 364.47M | 2.07B | -1.42B | -1.37B | -0.6765 |
SHMD
Schmid Group N V
|
5.35 | 297.48M | 52.15M | -21.46M | 0 | -0.4675 |
DWLD
Davis Select Worldwide ETF
|
43.81 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-06 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-06 | Downgrade | Craig Hallum | Buy → Hold |
| 2025-08-15 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2024-09-30 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-09 | Iniziato | Craig Hallum | Buy |
| 2024-05-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Skye Bioscience Inc Borsa (SKYE) Ultime notizie
SKYE SEC FilingsSkye Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings Miss: Whats the outlook for Skye Bioscience Incs sectorWeekly Investment Recap & High Accuracy Swing Trade Signals - baoquankhu1.vn
Skye Bioscience Signs Master Services Agreement With Lohman & Associates for Finance and Accounting Consulting - Minichart
Skye Bioscience reduces employee stock option exercise prices and appoints new CFO - Investing.com Australia
Skye Bioscience appoints John P. Sharp as CFO; Punit Dhillon and Tuan Diep have options repriced - TradingView
Skye Bioscience (SKYE) reprices 2.42M options and taps John Sharp as CFO - Stock Titan
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development - Bitget
Skye Bioscience doses first patient in nimacimab expansion study By Investing.com - Investing.com Australia
Skye Bioscience (SKYE) director receives 75,000 stock options at $0.615 strike - Stock Titan
Skye Bioscience (SKYE) CSO updates option awards with repricing and new grants - Stock Titan
Director at Skye Bioscience (NASDAQ: SKYE) receives 75,000-share stock option grant - Stock Titan
[Form 3/A] Skye Bioscience, Inc. Amended Initial Statement of Beneficial Ownership - Stock Titan
Skye Bioscience (SKYE) director awarded 75,000 stock options at $0.6150 - Stock Titan
Skye Bioscience (SKYE) director Paul A. Grayson receives 75,000 stock options - Stock Titan
Director at Skye Bioscience (SKYE) awarded 75,000 stock options at $0.615 - Stock Titan
Skye Bioscience (SKYE) COO receives repriced stock options - Stock Titan
Skye Bioscience (SKYE) reprices CEO stock options to $0.615 strike - Stock Titan
Skye Bioscience, Inc. initiates expansion study of nimacimab to assess exposure and safety - Traders Union
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study - MarketScreener
Skye Bioscience doses first patient in nimacimab expansion study - Investing.com
Skye tests higher nimacimab doses ahead of Phase 2b obesity combo - Stock Titan
Skye Bioscience, Inc. advances nimacimab dosing to target CB1 pathway - Traders Union
SKYE PE Ratio & Valuation, Is SKYE Overvalued - Intellectia AI
Aug Wrap: How does Skye Bioscience Inc perform in inflationary periods2026 Technical Overview & AI Enhanced Trading Signals - baoquankhu1.vn
Skye Bioscience Faces Nasdaq Listing Compliance Deficiency Notice - The Globe and Mail
Skye Bioscience, Inc. Files Form 8-K Announcing Notice of Delisting or Failure to Satisfy Nasdaq Continued Listing Rule (March 2026) 5 - Minichart
Skye Bioscience receives Nasdaq notice for minimum bid price deficiency By Investing.com - Investing.com Australia
Skye Bioscience receives Nasdaq notice for minimum bid price deficiency - Investing.com
Skye Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Skye Bioscience (SKYE) after shares stay under $1 minimum - Stock Titan
Skye Bioscience outlines 2026 milestones as nimacimab advances toward Phase IIb with new dosing strategy - MSN
Piper Sandler Sticks to Its Buy Rating for Skye Bioscience (SKYE) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF) - The Globe and Mail
Skye Bioscience Inc (SKYE) Q4 2025 Earnings Call Highlights: Pio - gurufocus.com
Cantor Fitzgerald reiterates Skye Bioscience stock rating at Neutral By Investing.com - Investing.com Canada
Citizens reiterates Skye Bioscience stock rating on weight loss data By Investing.com - Investing.com Canada
Skye Bioscience (SKYE) Advances Nimacimab Development with Promi - GuruFocus
Craig-Hallum Maintains SKYE BIOSCIENCE INC(SKYE.US) With Hold Rating - 富途牛牛
Skye Bioscience Q4 2025 Earnings Call Transcript - MarketBeat
SKYE: Additive weight loss and durable efficacy drive nimacimab's advancement as a GLP-1 add-on - TradingView
Skye Bioscience, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SKYE) 2026-03-10 - Seeking Alpha
Earnings call transcript: Skye Bioscience Q4 2025 highlights clinical advancements - Investing.com
Skye Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Skye (SKYE) Reinforces Nimacimab Strategy with Promising Data - GuruFocus
Q4 and full year results reveal momentum, Skye Bioscience, Inc. asserts - Traders Union
Skye Bioscience 2025 10-K: Net loss $(55.9M), Loss per share $(1.41) - TradingView
Skye Bioscience (NASDAQ: SKYE) highlights nimacimab obesity and metabolic pipeline - Stock Titan
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - ChartMill
Skye Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
Skye Bioscience Q4 2025 earnings preview - MSN
A Peek at Skye Bioscience's Future Earnings - Benzinga
Skye Bioscience Inc Azioni (SKYE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):